Ashwagandha's India Market Soars as Landmark Safety Trial Confirms Purity

India's booming Ashwagandha market is getting a massive credibility boost after a government-backed, 24-week clinical trial involving 1,200 adults found no evidence of liver or kidney damage from a standardized root extract. This landmark study, published in August 2026, addresses long-standing safety questions and is set to accelerate the demand for the adaptogenic herb both within India and globally. The trial, a randomized, double-blind, placebo-controlled effort across seven Indian sites, also observed that the Ashwagandha extract did not interfere with immunity generated by the COVISHIELD vaccine, further cementing its safety profile for prolonged use. This comes at a critical time as the Indian Ashwagandha supplements market, valued at approximately $68.4 million in 2025, is projected to surge to $148 million by 2033, driven by a global shift towards natural wellness products. Recent efforts by the Ministry of AYUSH to strictly enforce the use of roots over leaves in products, coupled with an advisory from the Food Safety and Standards Authority of India (FSSAI), underscore a push for higher quality and standardization in the industry. Looking ahead, this robust safety evidence is expected to unlock significant export opportunities for Indian Ashwagandha, with industry players and government bodies like the World Ashwagandha Council actively working to establish global standards and promote scientific validation. The potential for a Geographical Indication (GI) tag for Neemuch Ashwagandha is also on the horizon, promising premium pricing and enhanced global recognition for Indian-grown produce. This rigorous scientific validation marks a pivotal moment for traditional Ayurvedic medicine, paving the way for increased trust and broader acceptance in international markets.